Biogen (BIIB) PT Lowered to $343 at Wells Fargo
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $199.59 +1.22%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 52
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 52
Join SI Premium – FREE
Wells Fargo analyst Mohit Bansal lowered the price target on Biogen (NASDAQ: BIIB) to $343.00 (from $350.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Morgan Stanley Upgrades Telecom Argentina (TEO) to Overweight
- Dai-ichi Life Holdings, Inc (8750:JP) (DCNSF) PT Raised to JPY1,900 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
